Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

• Status: Terminated
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Basal arthritis of the thumb is a common condition with increased prevalence in post-menopausal women, obese persons, and the elderly. Surgical options are varied and efficacious, but not all patients are candidates for surgery. The successes and pitfalls of previous, similar trials are carefully considered in the creation of our own. Though steroid injection is the standard of care in basal joint arthritis, current data does not support its efficacy beyond placebo effect. No trial has yet examined the efficacy of botulinum toxin type A (BTX-A) injection into the basal thumb joint nor compared it to steroid. Since efficacy of steroid is questionable at best, our hope is that BTX-A injection of the basal joint might be the next great tool in treating this common, debilitating disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Missouri-Columbia
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; Lidocaine; onabotulinumtoxinA; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Radiographic evidence of basal joint arthritis

• Associated symptoms of basal joint arthritis including:

• Pain

• Decreased range of motion

• Decreased thumb strength

Exclusion Criteria:

• Persons under the age of 18

• Women who are currently pregnant

• Incompetent persons or persons otherwise incapable of effectively communicating the subjective experience of pain

• Prior surgery on the joint

• Injection in the last 12 months